Receptor-type tyrosine-protein kinase FLT3 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Receptor-type tyrosine-protein kinase FLT3 shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 22 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P36888. Start with acute myeloid leukemia, then reuse UniProt P36888 as the stable protein anchor across project notes and exports.
Start with acute myeloid leukemia, then reuse UniProt P36888 as the stable protein anchor across project notes and exports.
Receptor-type tyrosine-protein kinase FLT3 shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 22 linked drugs remain visible in the same block.
Start review with acute myeloid leukemia because it currently carries approved-linked support. Linked drugs include 4SC-203, AKN-028, AMG553, CRENOLANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyReceptor-type tyrosine-protein kinase FLT3
Review this target as Receptor-type tyrosine-protein kinase FLT3, mapped to UniProt P36888. Sequence length is 993 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Receptor-type tyrosine-protein kinase FLT3 as ChEMBL target CHEMBL1974, mapped to UniProt P36888. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Receptor-type tyrosine-protein kinase FLT3 is the right protein anchor across sources, using UniProt P36888 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute myeloid leukemia is currently framed as approved-linked support. It currently carries 22 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Receptor-type tyrosine-protein kinase FLT3 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P36888 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Receptor-type tyrosine-protein kinase FLT3 |
| UniProt Accession | P36888 |
| Component Type | Protein |
| Sequence Length | 993 aa |
Receptor-type tyrosine-protein kinase FLT3
Review this target as Receptor-type tyrosine-protein kinase FLT3, mapped to UniProt P36888. Sequence length is 993 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Receptor-type tyrosine-protein kinase FLT3 shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.
Start review with acute myeloid leukemia because it currently carries approved-linked support. Linked drugs include 4SC-203, AKN-028, AMG553, CRENOLANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5176837 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL5927784 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4744130 | 10.82 | IC50 | 0.015 | Preclinical |
| CHEMBL5195819 | 10.81 | Kd | 0.0154 | Preclinical |
| CHEMBL2105728 | 10.8 | Kd | 0.016 | Clinical |
| CHEMBL6002371 | 10.68 | Kd | 0.021 | Preclinical |
| CHEMBL5440655 | 10.62 | IC50 | 0.024 | Preclinical |
| CHEMBL4519741 | 10.42 | IC50 | 0.038 | Preclinical |
| CHEMBL2105728 | 10.22 | IC50 | 0.06 | Clinical |
| CHEMBL5641673 | 10.21 | IC50 | 0.061 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1,768 | 2,787 | 7.2 |
| cell-based format | 624 | 882 | 6.9 |
| assay format | 472 | 267 | 7.8 |
| cell membrane format | 2 | 1 | 7.6 |
| subcellular format | 1 | 67 | 6.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 20 | 3 | 8.1 |
| assay format | 4 | 428 | 6.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 4 | 4 | 6.7 |
| cell-based format | 3 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 14 | 6.4 |